The rise of Viagra initially sparked a surge for major pharmaceutical companies, nevertheless recent shifts present a murky scenario for investors. Generic versions are reducing revenue, and continued patent challenges https://sabrinaxoza084827.tokka-blog.com/41607717/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet